Prostate cancer has to be an individualized conversation. Every man’s prostate cancer is gonna be different from their brothers their uncles or their neighborsBook an appointment now, Call us!https://www.advancedurologyinstitute.com/individualized-treatment-for-prostate-cancer-dr-rishi-modh/Advanced Urology Institute5747 38th Ave N St. Petersburg, FL 33710 United StatesPhone: (727) 877–3387Fax: (727) 345-1951https://www.advancedurologyinstitute.com/aui-st-petersburg-office/Advanced Urology Institute Address: 12109 County Road 103 Oxford, Florida 34484 USA Phone: 855 298 2273 Fax: 352 350 8283 Email: firstname.lastname@example.org Website: http://www.advancedurologyinstitute.com Like us on Facebook:https://www.facebook.com/Advanced-Urology-Institute-1667209733546925/ Add us on Google+: https://plus.google.com/113064497631646108300/posts Follow us on Twitter: https://www.pinterest.com/advancedurology/ Pin us on Pinterest: https://twitter.com/AdvancedUrology Prostate Cancer, Urology, Urologist, Oxford, FL, Florida, Oxford FL
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the design and updated findings of the Phase II ZUMA-5 study evaluating axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (NHL) (NCT03105336). This study included patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL) who had received at least two lines of prior therapy. The study reported overall response rates (ORR) of 94% and 83% and complete response (CR) rates of 79% and 63% in patients with FL and MZL respectively. In addition, 57% and 50% of patients with FL and MZL respectively were still in remission at data cutoff. Axi-cel demonstrated a manageable safety profile, with mostly grade 1 or 2 cytokine release syndrome (CRS) and neurological events. In addition, patients with follicular lymphoma experienced less grade 3 or higher neurological adverse events than patients with MZL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on preliminary findings from a Phase II single-arm, open-label trial (NCT04762160) of tazemetostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, with rituximab in patients with relapsed/refractory follicular lymphoma (FL). Five patients have been enrolled so far and tazemetostat with rituximab have shown initial promise in patients, with further data yet to be published. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares an overview of the phase III RELEVANCE trial (NCT01650701) of rituximab and lenalidomide (R2) versus rituximab-chemotherapy followed by rituximab maintenance in patients with high tumor burden, untreated follicular lymphoma (FL). Six years after initial treatment, both treatment arms demonstrated similar efficacy and survival, highlighting R2 as a viable chemotherapy-free treatment option. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on the Phase II ELARA trial (NCT03568461), which assessed tisagenlecleucel (tisa-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with follicular lymphoma (FL). Tisa-cel improved progression-free survival across different subtypes of FL, including patients who progressed within 2 years (POD24). Patients who received tisa-cel in an outpatient setting also were less likely to require hospitalization, highlighting the ability for CAR T-cell therapies to be administered in an outpatient setting for patients with a low-risk disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, gives an overview of his talk on the clinical value of measurable residual disease (MRD) in indolent non-Hodgkin lymphoma (NHL), with a focus on follicular lymphoma (FL). Prof. Foà discusses the role of MRD monitoring in stratifying patients into different risk categories at diagnosis, as well as in refining the degree of clinical response to treatment and in predicting progression-free survival (PFS). In addition, the value of MRD in molecular testing and in helping treatment choice will also be examined. Despite its wide use in clinical trials and a large body of evidence demonstrating the benefits of MRD monitoring, it has not yet been implemented in clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
How to Obtain a Medical Marijuana Card fast In Winter Park, Orlando, FL. Are you looking for obtaining a medical marijuana card in Orlando?Since early 2017, Florida residents have been able to obtain a recommendation for medical marijuana treatment for specific qualifying conditions. Our physicians are board-certified and will evaluate you to determine if you may benefit from a medical marijuana card. Once you’ve received a recommendation, our helpful staff will assist you with every step of the process required to obtain your medical marijuana card. Some of these steps involve registering with the Florida Department of Health and locating a convenient medical marijuana treatment centers in your area.Visit Our Website: https://thecardclinics.com/